Progress report

Mechanisms and prediction of drug-induced liver disease

The hepatic microsomal enzyme system plays an outstanding role in the metabolism and detoxication of most drugs\(^1,2\), whereas the frequency of drug-induced liver disease increases steadily as 'a penalty for progress'\(^3\). Two main questions therefore arise: (1) Why do some drugs, ie, by which cellular mechanism(s), provoke side effects upon the liver, and (2) how might we predict them? The purpose of this review is to define the relations between drugs and the liver. The recent metabolic and molecular aspects of drug hepatotoxicity will be emphasized, as well as the limits of animal testing.

**Hepatic Response to Drugs**

The response of the liver to drugs can be classified into four main types: (1) idiosyncrasy, which might in fact correspond either to hypersensitivity or abnormality of drug metabolism; (2) drug interactions, including enzyme induction; (3) direct hepatotoxicity; (4) interferences with bilirubin disposal. Animal testing appears to be of help in predicting the three latter types as well as many abnormalities of drug metabolism. Unfortunately, it provides no information concerning hypersensitivity, which probably yields in man the highest incidence of liver injuries\(^4,5\), sometimes severe. In addition, the incidence of such side effects caused by a certain drug is usually low, so that they may be missed for years. As an example, a convincing report of hepatic disorder due to papaverine\(^6\) came as a surprise more than half a century after its first use in man\(^7\). Moreover, as far as hypersensitivity is concerned, there is no definite relation between the chemical structure of a compound and its effects on the liver. Yet the existence of a few cross sensitivities may be of some help in prediction: sensitivity to chlorpromazine may be associated with sensitivity to promethazine\(^8\); sensitivity to halothane\(^9\) could resemble that due to other halogenated anaesthetics, eg, methoxyflurane\(^10\) and fluroxene\(^11\). Such facts, however, could sometimes be better explained on the basis of possible metabolic peculiarities which will be considered further.

**Factors Influencing the Hepatic Response to Drugs**

There are considerable individual variations in the response to drugs to be considered before any conclusion can be reached from animal testing\(^2,12,13\). They mainly depend on dose, species, sex, age, nutrition, associated drugs, preexisting liver function, and genetic factors.

According to species, the hepatic disposal of a given compound may be entirely different. For example, rifampicin is highly toxic in the dog, which is unable to desacetylate it efficiently, compared with man whose liver excretes more than 80% of rifampicin as desacetyl-metabolites\(^14\). Another example is
Mechanisms and prediction of drug-induced liver disease

that of methotrexate, which the rabbit metabolizes, whereas other species, such as mouse and man, do not metabolize the drug; based on the known toxicity of non-metabolized methotrexate, its enzymatic cleavage was used successfully in the mouse in order to prevent the toxicity of the drug.

The biological half-lives of most drugs and hormones are genetically determined. Studies with 14C-chlordiazepoxide revealed plasma half-lives of 22 to 24 hr in man as against 10-14 hr in the dog and four to six hr in the rat. Metabolic breakdown of chlordiazepoxide is, however, extensive in all three of these species, and the major metabolite formed is the same in man and dog, although different in the rat. In addition, large differences in half-lives of various drugs have been found according to the strain in rats or rabbits. In man, a thirty-fold variation in the plasma level is possible for many drugs, whereas comparable concentrations are regularly achieved in identical twins. Such facts may greatly influence the pharmacological responses and the possible toxic effects of drugs.

Age is also of importance: newborns in most species, including man, have an inefficient hepatic microsomal enzyme system which in adults metabolizes a wide variety of drugs; this makes it impossible to calculate for a newborn a drug dosage based on fractions of an adult dose.

There are surprisingly few data about the influence on drug disposal of preexisting liver dysfunction. This could be related to (1) the absence of a satisfactory method of studying needle biopsy samples, and (2) the fact that such biopsies are usually not performed during severe hepatic disease. Some enzyme activities were, however, measured, and appeared to be only affected in the most severe cases. Hepatic impairment has been found to alter or not the plasma disappearance rate of phenylbutazone; to alter that of chloramphenicol and of isoniazid. Plasma levels of rifampicin were higher in cirrhotic patients than in patients with a normal liver. Half-lives of salicylic acid, aminopyrine, dicoumarol, and antipyrine were not different in cirrhotic and control patients. Following portacaval shunt in the rat, specific activities of the microsomal enzymes aniline hydroxylase and nitroreductase were found to be low. To summarize, it is conceivable that liver dysfunction would yield high plasma levels mainly of those drugs being excreted with an important biliary concentration, whereas impairment of drug metabolism would appear only in severe hepatocellular failure.

Many possible drug interactions will also influence the hepatic response to drugs. An impressive number of substances, including hundreds of drugs, and especially phenobarbitone, are known to induce the non-specific microsomal drug-metabolizing enzyme system. These inducing agents can lower considerably the blood levels of most drugs which are normally metabolized by the liver. As the pharmacological activity of drugs is most often due to the parent compound, diminution of therapeutic efficiency will ensue. A striking example is that of phenobarbitone given together with coumarin anticoagulants: severe haemorrhagic accidents may appear when phenobarbitone therapy is suppressed.

As far as the toxicity of drugs is concerned, there are two possibilities to consider: (1) the drug itself is toxic, as its metabolites are not; (2) toxicity is due to one of the metabolites. One can clearly predict that in the first case, which is the most frequent, enzyme induction will protect, as in the second it will enhance the toxic effects. But a few substances seem able to reduce the hepatic metabolism of various drugs: allopurinol and nortriptyline inhibit...
in man the metabolism of antipyrine and bis-hydroxycoumarin; chloramphenicol increases in man the serum levels of unchanged tolbutamide and diphenylhydantoin; halothane depresses the metabolism of various barbiturates and aminopyrine in the rat; progesterone and its metabolites act in vitro as inhibitors of the hepatic mixed-function oxidase system; abnormalities of serum transaminases during combined rifampicin and isoniazid therapy are more likely to appear in those patients who are 'slow acetylator' phenotypes for isoniazid.

The hepatic disposal of hormones, and especially of steroids, is very similar to that of drugs. In this respect, it is worth noting that the circadian rhythm which exists in hepatic drug-metabolizing activity in the intact rat was no longer present in adrenalectomized animals. This circadian cycle influenced the methadone-induced mortality in the rat. On the other hand, drugs may act on steroid metabolism, for the hydroxylated metabolites of chlorpromazine inhibit the conjugation of hydrocortisone, as the demethylated metabolites of chlorpromazine are able to stimulate it.

**Direct Hepatotoxicity**

Direct hepatotoxicity can be defined by a constant action of a given compound and a strictly dose-dependent effect. It may lead either to zonal liver cell necrosis or to intrahepatic cholestasis.

**Cellular Injury**

There are only a few drugs able to induce hepatocellular injury by direct toxicity, because this kind of hepatitis-like reaction is often severe, making many of the causative agents of unacceptable risk. Chloroform, various antineoplastic antibiotics, tannic acid, and the tetracyclines belong to that group. The cellular mechanism of their hepatotoxicity has been mainly studied in animals given carbon tetrachloride (CCl₄) or ethionine. Only the most currently accepted hypothesis will be summarized here.

The intense steatosis that these poisons usually provoke seems to be mainly the result of early impaired protein synthesis. The first effect could be a marked decrease of intracellular ATP resulting in a block of m-RNA synthesis, and therefore of protein synthesis as well. Lack of the protein moiety of the lipoproteins ensues, explaining the accumulation of triglycerides; the steatosis is the result of the absence of the carrier protein to which triglycerides must be attached to be moved out of the cell. On the other hand, liver cell necrosis provoked by CCl₄ could be due to metabolites of CCl₄, such as CCl₃ free radicals. These free radicals, with a highly reactive unpaired electron, would directly attack the mitochondrial membrane, blocking the oxidative phosphorylation.

Although all these cellular mechanisms are still not proved to be the only explanation for the action of all poisons on the liver they suggest several lines of enquiry. The role of metabolites of CCl₄ is well supported by the enhancement of CCl₄ toxicity by previous treatment with enzyme inducers. It is interesting to speculate that some similarities might exist between the toxic effect on the liver of CCl₄ and halothane. Although several arguments support the theory that in man the adverse effects of halothane remain unpredictable, this does not exclude true hepatotoxicity in predisposed patients. The metabolism of halothane has been extensively studied.
and includes microsomal dechlorination. A toxic metabolite is conceivable, which would explain the increased risk which has been suggested in the case of previous administration of phenobarbitone in man and in the rat. The induction of halothane metabolism by halothane itself has been demonstrated in mice; if this were to happen in man, as has been suggested, it could play some role in the higher incidence of liver necrosis following repeated exposure to the anaesthetic. Very similar mechanisms can be incriminated for methoxyflurane which undergoes a similar metabolic fate to that of halothane, and induces the dechlorinating system in animals.

The toxicity of methoxyflurane in man could be dose-dependent, as it is correlated with renal dysfunction and that of fluroxene was claimed to be enhanced by the previous administration of enzyme inducers. Finally, the toxicity of a number of halogenated aromatic hydrocarbons, possibly including chloroform, could at least be partly explained on a metabolic basis. Similar mechanisms have also been suggested for chloramphenicol, whereas pretreatment with phenobarbitone has a protective effect against a variety of agents, including toluene and benzene or aflatoxin.

**INTRAHEPATIC CHOLESTASIS**

Various drugs, including mainly such hormones as 17-alpha alkyl substituted oestrogens or other steroids, are able to provoke intrahepatic cholestasis by direct toxicity. Such cholestasis is highly predictable, and may be studied in any animal species. The drugs which are concerned include the oestrogenic compounds found in contraceptive pills. The rarity of jaundice due to oral contraceptives makes it likely that additional factors, possibly genetic, exist in predisposed women.

The cellular mechanisms explaining drug-induced cholestasis have been extensively studied. In the rat at least, an early and striking effect is a diminution in bile flow. This could be related to increased permeability of the biliary tree to water. It could also be explained by a decrease in the so-called bile salt-independent fraction of bile secretion. This last hypothesis is in accordance with the fact that only those oestrogens able to diminish the bile flow were found also to decrease the Na+K+ATPase in rat liver plasma membrane, as it was suggested that this ATPase could provide the driving force for the bile salt-independent fraction of choleretic cholestasis. Cholestatic drugs could also interfere with the hepatic disposal of bile salts. This at least was claimed for steroids and chlorpromazine. The former have been shown to inhibit the conversion of cholate into taurocholate; such impairment could contribute to cholestasis, for the rat at least is unable to excrete cholate in its bile. An alternate interference of cholestatic drugs on bile acid metabolism has been suggested as a result of hypoactive hypertrophic smooth endoplasmic reticulum in the hepatocyte. This theory refers to an excess of the poorly soluble monohydroxy bile acids resulting from enhanced synthesis of cholesterol, the precursor of bile acids, due to hypertrophic smooth endoplasmic reticulum. Hypoactivity of smooth endoplasmic reticulum would account for reduced enzymatic activity, with impaired ring hydroxylation of cholesterol.

As far as amine-containing drugs, such as chlorpromazine, are concerned, a direct impairment of micelle formation has been suggested: native chlorpromazine could form insoluble complexes with bile salts, as chlorpromazine metabolites would not. In addition, non-metabolized chlorpromazine has caused precipitation of biliary proteins in vitro. Bearing in mind a possible
induction of chlorpromazine metabolism by the drug itself, it is interesting to speculate that such an action could account for the so-called 'desensitization' which frequently occurs in man during prolonged administration of phenothiazines. This again would be an example of a metabolic basis for a liver injury apparently due to hypersensitivity, supposing that the normally occurring adaptation to the drug could be lacking in the few individuals in whom chlorpromazine causes overt cholestatic jaundice.

Interference of Drugs with the Disposal of Bilirubin

A few drugs are able to interfere with the hepatic disposal of bilirubin and cholephilic dyes. This kind of side effect is highly predictable from animal testing; it is usually of little practical importance in man as creating only moderate and transient unconjugated hyperbilirubinaemia, but its study allowed experimental models to be designed which appeared of value in improving our knowledge of liver physiology. The competition, however, for plasma protein binding between drugs and bilirubin and their role on kernicterus will not be considered here. Various drugs, which all seem to be organic anions able to be concentrated within the liver cell and bile, interfere with the first stage of liver cell transport, i.e., uptake. These drugs include mainly bunamiodyl, male fern extracts, novobiocin, rifampicin, and rifamycin SV. Such competition for uptake could be due either to interference with hypothetical membrane carriers, or to competition for binding at the site of cytoplasmic anion-accepting proteins, as has been suggested at least for bunamiodyl and flavaspideic acid.

There have been conflicting reports on drugs which may interfere with the conjugation of bilirubin. In work comparing the effect on glucuronyl-transferase activity in vitro of bunamiodyl, rifampicin, and novobiocin, only the last compound inhibited enzyme activity; the assays were performed on liver homogenates, according to a method using bilirubin as substrate. The lack of inhibition which was found for bunamiodyl is in contradiction to a previous report, in which other methods were used. However, species differences could exist as far as glucuronyl-transferase activity is concerned: with the steroids incriminated as the possible cause of breast milk jaundice different behaviour between human and rat glucuronyl-transferase activity was observed. Finally, all these drugs have also a cholestatic effect with decreased bile flow, impaired biliary excretion of bilirubin, and increased hepatic storage. Such increased storage, which is only seen in experiments of long duration, contrasts with the reduced storage which was observed shortly after a single dose of the drug; the former could be explained on the basis of impaired excretion, as the latter would reflect the reduction in hepatic uptake. Such impaired excretion is in any case of interest, for there is a relationship between bile flow and excretory function of the liver. This also leads to speculation that the enhanced excretion of various cholephilic anions, which has been observed following chronic administration of phenobarbitone, could be related at least in part to its choleretic effect.

Concluding Remarks

The most striking development in the field of drug-induced liver disease is the molecular approach to toxicity, including the cellular mechanisms of
Mechanisms and prediction of drug-induced liver disease

steatosis, necrosis, cholestasis, and competition phenomena. Based on this type of approach, and in order to prevent toxicity, new therapeutic possibilities arise, such as those acting on the drug-metabolizing systems; in the near future perhaps the efficacy of various actions of drugs could also be adapted by modifying bile flow. Species differences, however, as well as the number of drug interactions, make valueless many of the conventional ways of testing the response of the liver to drugs. It appears that testing a new compound should never be limited, as it too often has been, to light microscopy of the liver and the determination of a lethal dose which varies greatly from species to species, and even from strain to strain. Animal testing of a new compound, as far as the liver is concerned, should be conducted in acute and chronic experiments in various species and should try to answer at least the following questions: (1) Is the drug metabolized, and if so, how? (2) Is the toxicity due to the parent compound and/or to its metabolites? (3) Does chronic administration of the drug influence its own metabolism? (4) Which are the compounds able to interact with it? For many drugs, old or new, the answers to these questions remain unknown. In such cases, probably the simplest way at the moment to avoid the possible side effects will be to remember that 'a major cause of preventable drug reactions is that too many pills are prescribed'.”

PIERRE BERTHELOT,
Unité de Recherches INSERM U-99,
Hôpital Henri Mondor,
94010 Créteil, France

References

Pierre Berthelot

338


Mechanisms and prediction of drug-induced liver disease


